|
Market Cap | 40.64M | EPS (ttm) | -3.03 |
P/E | - | EPS this Y | -2.29% |
Forward P/E | - | EPS next Y | 40.44% |
PEG | - | EPS past 5Y | -114.14% |
P/S | - | EPS next 5Y | - |
P/B | 0.43 | EPS Q/Q | -25.12% |
Dividend | - | Sales Q/Q | - |
Insider Own | 33.29% | Inst Own | 64.74% |
Insider Trans | -2.65% | Inst Trans | 4.19% |
Short Float | 11.49% | Earnings | May 13/a |
Analyst Recom | 3.00 | Target Price | 2.25 |
Avg Volume | 607.81K | 52W Range | 1.50 - 32.42 |
|
|
Jun-18-24 | Downgrade |
Wells Fargo |
Overweight → Equal Weight |
$35 → $2 |
Jun-18-24 | Downgrade |
TD Cowen |
Buy → Hold |
|
Jun-18-24 | Downgrade |
Evercore ISI |
Outperform → In-line |
$27 → $2 |
|
|
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Verwijs Marinus | CHIEF TECHNICAL OFFICER | Jun 14 '24 | Option Exercise | 14.59 | 10,600 | 154,654 | 10,600 | Jun 14 06:00 PM | Eldridge George A | SEE REMARKS | Jun 14 '24 | Option Exercise | 2.14 | 15,000 | 32,100 | 20,022 | Jun 14 06:00 PM | Eldridge George A | SEE REMARKS | Jun 14 '24 | Sale | 25.03 | 15,000 | 375,450 | 5,022 | Jun 14 06:00 PM | Verwijs Marinus | CHIEF TECHNICAL OFFICER | Jun 14 '24 | Sale | 25.00 | 10,600 | 265,000 | 0 | Jun 14 06:00 PM | Gillies Hunter | CHIEF MEDICAL OFFICER | Jun 13 '24 | Option Exercise | 2.14 | 6,000 | 12,840 | 11,602 | Jun 14 06:00 PM |
|
|
|
|
Market Cap | 13.02B | EPS (ttm) | 3.23 |
P/E | 12.40 | EPS this Y | 33.29% |
Forward P/E | 5.56 | EPS next Y | 17.68% |
PEG | 0.65 | EPS past 5Y | 1.22% |
P/S | 0.98 | EPS next 5Y | 19.00% |
P/B | 27.90 | EPS Q/Q | -32.86% |
Dividend | 2.33% | Sales Q/Q | 42.49% |
Insider Own | 0.48% | Inst Own | 99.94% |
Insider Trans | -25.03% | Inst Trans | -0.24% |
Short Float | 1.32% | Earnings | Apr 30/a |
Analyst Recom | 2.00 | Target Price | 43.11 |
Avg Volume | 2.57M | 52W Range | 24.65 - 41.64 |
|
|
Jun-18-24 | Downgrade |
UBS |
Buy → Neutral |
$40 → $43 |
|
|
Equitable Holdings, Inc. engages in the provision of financial services. It operates through the following segments: Individual Retirement, Group Retirement, Investment Management and Research, Protection Solutions, Wealth Management, Legacy, and Corporate and Other. The Individual Retirement segment includes annuity products, which primarily meet the needs of individuals saving for retirement or seeking retirement income. The Group Retirement segment offers tax-deferred investment and retirement services or products to plans sponsored by educational entities, municipalities and not-for-profit entities, as well as small and medium-sized businesses. The Investment Management and Research segment provides investment management, research and related services. The Protection Solutions segment focuses on life insurance products on attractive protection segments such as VUL insurance and IUL insurance and employee benefits business on small and medium-sized businesses. The Wealth Management segment refers to the discretionary and non-discretionary investment advisory accounts, financial planning and advice, insurance, and annuity products. The Legacy segment consists of capital intensive fixed-rate GMxB business written in the Individual Retirement market prior to 2011. The company was founded by Henry B. Hyde in 1859 and is headquartered in New York, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
HURD JEFFREY J | Chief Operating Officer | Jun 14 '24 | Sale | 39.62 | 9,969 | 394,992 | 121,521 | Jun 17 04:50 PM | HURD JEFFREY J | Chief Operating Officer | May 15 '24 | Sale | 40.42 | 9,969 | 402,945 | 131,093 | May 17 04:34 PM | BERNSTEIN SETH P | See Remarks | May 02 '24 | Option Exercise | 20.81 | 122,655 | 2,552,563 | 241,133 | May 03 05:00 PM | BERNSTEIN SETH P | See Remarks | May 02 '24 | Sale | 38.06 | 152,473 | 5,802,650 | 88,660 | May 03 05:00 PM | Pearson Mark | President and CEO | Apr 15 '24 | Option Exercise | 21.34 | 20,000 | 426,800 | 715,025 | Apr 16 05:00 PM |
|
|
|
|
Market Cap | 28.08B | EPS (ttm) | 9.54 |
P/E | 27.51 | EPS this Y | 75.64% |
Forward P/E | 12.43 | EPS next Y | 55.24% |
PEG | 0.47 | EPS past 5Y | 41.58% |
P/S | 7.88 | EPS next 5Y | 58.00% |
P/B | 4.07 | EPS Q/Q | 454.63% |
Dividend | - | Sales Q/Q | 44.83% |
Insider Own | 5.60% | Inst Own | 90.31% |
Insider Trans | -2.53% | Inst Trans | 2.01% |
Short Float | 5.57% | Earnings | May 01/a |
Analyst Recom | 1.65 | Target Price | 283.76 |
Avg Volume | 2.70M | 52W Range | 129.21 - 306.77 |
|
|
Jun-18-24 | Downgrade |
Janney |
Buy → Neutral |
|
|
|
First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Tempe, AZ. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Widmar Mark R | Chief Executive Officer | Jun 03 '24 | Sale | 273.26 | 36,692 | 10,026,456 | 81,861 | Jun 04 05:34 PM | Dymbort Jason E. | General Counsel and Secretary | Jun 03 '24 | Sale | 273.26 | 2,308 | 630,684 | 13,351 | Jun 04 05:32 PM | Bradley Alexander R. | Chief Financial Officer | May 30 '24 | Sale | 274.69 | 16,051 | 4,409,007 | 30,652 | May 31 07:14 PM | Koralewski Michael | Chief Supply Chain Officer | May 30 '24 | Sale | 272.92 | 4,646 | 1,267,986 | 7,766 | May 31 07:12 PM | Sweeney Michael T | Director | May 30 '24 | Sale | 273.50 | 4,000 | 1,094,020 | 16,692 | May 31 07:11 PM |
|
|
| |
|
Market Cap | 55.89M | EPS (ttm) | -0.72 |
P/E | - | EPS this Y | -11.45% |
Forward P/E | - | EPS next Y | 23.16% |
PEG | - | EPS past 5Y | 18.87% |
P/S | 118.92 | EPS next 5Y | - |
P/B | 0.71 | EPS Q/Q | 12.72% |
Dividend | - | Sales Q/Q | 123.70% |
Insider Own | 18.85% | Inst Own | 60.18% |
Insider Trans | 0.14% | Inst Trans | 2.23% |
Short Float | 4.98% | Earnings | May 14/b |
Analyst Recom | 1.40 | Target Price | 3.17 |
Avg Volume | 529.04K | 52W Range | 0.75 - 4.14 |
|
|
Jun-18-24 | Downgrade |
Oppenheimer |
Outperform → Perform |
|
|
|
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
LEVIN JEREMY M | CEO | Mar 18 '24 | Buy | 2.76 | 18,248 | 50,364 | 3,616,715 | Mar 20 05:22 PM |
|
|
|
|
Market Cap | 293.98M | EPS (ttm) | -3.36 |
P/E | - | EPS this Y | 39.51% |
Forward P/E | - | EPS next Y | -34.28% |
PEG | - | EPS past 5Y | -50.05% |
P/S | 7.25 | EPS next 5Y | - |
P/B | 0.64 | EPS Q/Q | 113.26% |
Dividend | - | Sales Q/Q | - |
Insider Own | 12.31% | Inst Own | 113.65% |
Insider Trans | -0.48% | Inst Trans | -0.93% |
Short Float | 28.13% | Earnings | May 07/b |
Analyst Recom | 2.20 | Target Price | 12.11 |
Avg Volume | 653.22K | 52W Range | 8.25 - 30.53 |
|
|
Jun-18-24 | Downgrade |
Wells Fargo |
Overweight → Equal Weight |
|
Jun-18-24 | Downgrade |
Wedbush |
Neutral → Underperform |
$15 → $4 |
Jun-18-24 | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
$38 → $8 |
Jun-18-24 | Downgrade |
Jefferies |
Buy → Hold |
$42 → $6 |
|
|
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in New York, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Gallagher Cam | President, Interim CFO | May 31 '24 | Sale | 11.98 | 9,597 | 114,972 | 633,680 | May 31 06:27 PM | HAUSMAN DIANA | Chief Medical Officer | May 09 '24 | Sale | 12.62 | 3,356 | 42,353 | 373,876 | May 09 07:46 PM | Epperly Melissa B, | Chief Financial Officer | Feb 12 '24 | Sale | 11.44 | 2,573 | 29,435 | 451,449 | Feb 12 08:22 PM | Gallagher Cam | President | Feb 12 '24 | Sale | 11.44 | 1,173 | 13,419 | 643,277 | Feb 12 08:21 PM | Gallagher Cam | President | Feb 02 '24 | Sale | 11.54 | 11,552 | 133,310 | 644,450 | Feb 05 07:13 PM |
|
|
|
|